Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DWH79Q
|
|||
| Drug Name |
LY-CoV555
|
|||
| Synonyms |
LY3819253
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [1] | |
| Company |
Lilly; AbCellera
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 spike glycoprotein (S) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04497987) A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2). U.S. National Institutes of Health. | |||
| REF 2 | Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.